This phase 0 trial indicated that IFNγ can convert a “cold” into a “hot” tumour in patients with synovial sarcoma and myxoid/round cell liposarcoma, and the combination with anti-PD1 treatment may produce some advantages in the treatment of this patients. The gene discussed is IFNG; the disease is neoplasm.